Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-02-09

Clinical Trial Update: Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating combination therapy with 3BNC117 and 10-1074 in HIV-infected individuals was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • 10-1074
  • 3BNC117

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV | Phase 1 | Status: TERMINATED | Results posted: 2022-02-09